Laurel Wealth Advisors LLC Has $898,000 Stock Holdings in IQVIA Holdings Inc. (NYSE:IQV)

Laurel Wealth Advisors LLC lifted its stake in shares of IQVIA Holdings Inc. (NYSE:IQV) by 3.2% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 4,572 shares of the medical research company’s stock after purchasing an additional 140 shares during the quarter. Laurel Wealth Advisors LLC’s holdings in IQVIA were worth $898,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Canada Pension Plan Investment Board raised its position in shares of IQVIA by 6.6% in the 2nd quarter. Canada Pension Plan Investment Board now owns 3,403,488 shares of the medical research company’s stock valued at $719,634,000 after buying an additional 211,653 shares in the last quarter. Farallon Capital Management LLC raised its position in IQVIA by 3.1% during the second quarter. Farallon Capital Management LLC now owns 2,923,032 shares of the medical research company’s stock valued at $618,046,000 after purchasing an additional 86,870 shares in the last quarter. FMR LLC boosted its holdings in shares of IQVIA by 38.7% in the 3rd quarter. FMR LLC now owns 2,887,342 shares of the medical research company’s stock valued at $684,213,000 after purchasing an additional 804,963 shares in the last quarter. JPMorgan Chase & Co. increased its stake in shares of IQVIA by 46.2% in the 3rd quarter. JPMorgan Chase & Co. now owns 1,845,711 shares of the medical research company’s stock valued at $437,378,000 after purchasing an additional 583,396 shares during the last quarter. Finally, Impax Asset Management Group plc raised its holdings in shares of IQVIA by 9.7% during the 3rd quarter. Impax Asset Management Group plc now owns 1,793,010 shares of the medical research company’s stock worth $423,885,000 after buying an additional 157,809 shares in the last quarter. Institutional investors and hedge funds own 89.62% of the company’s stock.

IQVIA Trading Down 3.2 %

IQV opened at $198.12 on Wednesday. IQVIA Holdings Inc. has a twelve month low of $187.62 and a twelve month high of $261.73. The company has a fifty day moving average of $201.43 and a 200-day moving average of $221.61. The stock has a market cap of $35.96 billion, a PE ratio of 26.00, a price-to-earnings-growth ratio of 2.05 and a beta of 1.48. The company has a quick ratio of 0.81, a current ratio of 0.81 and a debt-to-equity ratio of 1.76.

Analyst Upgrades and Downgrades

IQV has been the topic of a number of recent analyst reports. StockNews.com cut IQVIA from a “buy” rating to a “hold” rating in a research report on Thursday, November 28th. Robert W. Baird lowered their price objective on shares of IQVIA from $213.00 to $212.00 and set a “neutral” rating for the company in a research report on Wednesday, December 11th. Redburn Atlantic began coverage on shares of IQVIA in a research report on Monday, October 14th. They issued a “buy” rating and a $276.00 target price on the stock. TD Cowen lowered their price target on shares of IQVIA from $270.00 to $255.00 and set a “buy” rating for the company in a report on Friday, November 1st. Finally, Evercore ISI reduced their price objective on IQVIA from $270.00 to $265.00 and set an “outperform” rating on the stock in a research report on Tuesday, October 8th. Four analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $255.82.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.